RAPT Therapeutics, Inc. (NASDAQ:RAPT) Short Interest Up 39.9% in May

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 5,010,000 shares, an increase of 39.9% from the April 30th total of 3,580,000 shares. Based on an average daily trading volume, of 912,800 shares, the short-interest ratio is currently 5.5 days. Currently, 15.3% of the company's stock are short sold.

RAPT Therapeutics Trading Up 7.7%

Shares of RAPT traded up $0.07 during midday trading on Tuesday, hitting $1.01. 376,238 shares of the company's stock traded hands, compared to its average volume of 903,510. RAPT Therapeutics has a 1 year low of $0.71 and a 1 year high of $4.23. The firm's fifty day moving average is $0.93 and its 200-day moving average is $1.12. The stock has a market capitalization of $133.61 million, a price-to-earnings ratio of -0.36 and a beta of -0.04.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.23. On average, equities research analysts anticipate that RAPT Therapeutics will post -2.14 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. UBS Group lowered their target price on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. HC Wainwright upgraded RAPT Therapeutics to a "strong-buy" rating and set a $6.00 target price for the company in a report on Thursday, May 22nd. Finally, Wall Street Zen upgraded RAPT Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, four have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $3.00.

Institutional Trading of RAPT Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Picton Mahoney Asset Management lifted its holdings in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after purchasing an additional 14,697 shares during the last quarter. Los Angeles Capital Management LLC increased its position in shares of RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company's stock valued at $348,000 after acquiring an additional 18,558 shares during the period. Simplicity Wealth LLC acquired a new position in shares of RAPT Therapeutics in the 1st quarter valued at $25,000. Exchange Traded Concepts LLC increased its position in shares of RAPT Therapeutics by 27.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company's stock valued at $139,000 after acquiring an additional 24,662 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after acquiring an additional 25,130 shares during the period. Hedge funds and other institutional investors own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.